“Life Science-Related Investigations at the US International Trade Commission,” Jenner & Block Webinar
Event
August 2, 2021
On August 12, Jenner & Block Partners Mark Davis and Ronald J. Pabis and Associate Susan A. O’Brien will present a CLE webinar on life science-related investigations at the US International Trade Commission (ITC). Partner Louis E. Fogel will moderate the discussion. The program will examine the use of ITC Section 337 investigations for life sciences products, including pharmaceuticals and medical devices. The presenters will cover important issues arising in such cases, including the use of public interest factors, indirect infringement, design around alternatives, the substantive elements of proof, and the procedure used by the ITC in these types of investigations. The program will begin at 12 pm ET. Please email dl_webinar@jenner.com if you are interested in attending. Space is limited. Mr. Davis is co-chair of the ITC Section 337 Practice. He represents multinational, domestic, and start-up companies regarding intellectual property and related international trade, data privacy, unfair competition, and antitrust matters. He has litigated disputes before US district courts throughout the country and the Court of Appeals for the Federal Circuit and has been involved in more than 100 section 337 investigations before the ITC. Mr. Fogel is co-chair of the Life Sciences Practice and a member of the Patent Litigation and Counseling Practice. He represents clients on a range of intellectual property matters, with an emphasis on patent and trade secret litigation. Mr. Fogel’s litigation experience spans a wide array of technologies and industries, including biological drugs, pharmaceuticals, medical devices, chemicals, consumer electronics, and telecommunications. Mr. Pabis is co-chair of the ITC Section 337 Practice. He represents technology companies in patent litigation and patent licensing disputes at all stages of the litigation process. In addition, he has handled and tried a number of Section 337 investigation hearings before the ITC. Ms. O’Brien is an associate in the firm’s Litigation Department and the Patent Litigation and Counseling Practice.
Related Lawyers
Related Capabilities
Event
August 2, 2021
On August 12, Jenner & Block Partners Mark Davis and Ronald J. Pabis and Associate Susan A. O’Brien will present a CLE webinar on life science-related investigations at the US International Trade Commission (ITC). Partner Louis E. Fogel will moderate the discussion. The program will examine the use of ITC Section 337 investigations for life sciences products, including pharmaceuticals and medical devices. The presenters will cover important issues arising in such cases, including the use of public interest factors, indirect infringement, design around alternatives, the substantive elements of proof, and the procedure used by the ITC in these types of investigations. The program will begin at 12 pm ET. Please email dl_webinar@jenner.com if you are interested in attending. Space is limited. Mr. Davis is co-chair of the ITC Section 337 Practice. He represents multinational, domestic, and start-up companies regarding intellectual property and related international trade, data privacy, unfair competition, and antitrust matters. He has litigated disputes before US district courts throughout the country and the Court of Appeals for the Federal Circuit and has been involved in more than 100 section 337 investigations before the ITC. Mr. Fogel is co-chair of the Life Sciences Practice and a member of the Patent Litigation and Counseling Practice. He represents clients on a range of intellectual property matters, with an emphasis on patent and trade secret litigation. Mr. Fogel’s litigation experience spans a wide array of technologies and industries, including biological drugs, pharmaceuticals, medical devices, chemicals, consumer electronics, and telecommunications. Mr. Pabis is co-chair of the ITC Section 337 Practice. He represents technology companies in patent litigation and patent licensing disputes at all stages of the litigation process. In addition, he has handled and tried a number of Section 337 investigation hearings before the ITC. Ms. O’Brien is an associate in the firm’s Litigation Department and the Patent Litigation and Counseling Practice.
Related Lawyers
Related Capabilities
News and Insights
Event
Amanda Shafer Berman to Speak on Energy and Administrative Law at WEN-DC Webinar
As the Supreme Court's new Term begins, Jenner & Block Partner Amanda Shafer Berman will join a Women's Energy Network of Washington, DC (WEN-DC) webinar on how the Court's decisions are shaping the energy sector.
October 14, 2026
Publications
Partner Amanda Shafer Berman Quoted in Bloomberg Law on Senate Permitting Overhaul Bill
Partner Amanda Shafer Berman was quoted in an October 5 Bloomberg Law article, "Permitting Deal Gives Projects Defense Against Litigation Delays," on the Senate's new permitting overhaul package and its expected impact on litigation over federal permitting reversals.
October 2026
Event
Partner John Storino to Speak at Sandpiper Partners' “AI and Outside Counsel Guidelines Roundtable”
On October 8, Partner John Storino will serve as a panelist at the “AI and Outside Counsel Guidelines Roundtable,” hosted by Sandpiper Partners in Chicago.
October 8, 2026
Event
Partner Meghan Greenfield to Speak on Supreme Court Climate Case at Edison Electric Institute's Fall Legal Conference
On Wednesday, October 7, Partner Meghan Greenfield will speak on a panel titled "Boulder County v. Suncor Energy: What the Supreme Court's Climate Case Means for the Energy Industry" at the Edison Electric Institute's Fall Legal Conference in Salt Lake City, Utah.
October 7, 2026
Publications
The Form Rules Everything: A Seventh Circuit Ruling on ERISA's Substantial Compliance Doctrine
Partner Joseph Torres and Special Counsel Jennifer Beach authored an article for Employee Relations Law Journal examining the Seventh Circuit's decision in Packaging Corp. of America Thrift Plan for Hourly Employees v. Langdon, a ruling that addresses both the standard of review in ERISA interpleader actions and the continued viability of the substantial compliance doctrine for changing plan beneficiaries.
October 5, 2026